Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Treatment of SLE: bridging the gap from clinical trials to the clinic

Meeting abstract

Historical overview

Leonard H Calabrese

  • Correspondence: Leonard H Calabrese

Author Affiliations

Professor of Medicine, Cleveland Clinic Lerner College of Medicine, RJ Fasenmyer Chair of Clinical Immunology, Cleveland Clinic Foundation, Cleveland, Ohio, USA

Arthritis Research & Therapy 2013, 15(Suppl 2):A2  doi:10.1186/ar4220

The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/15/S2/S2


Published:11 July 2013

© 2013 Calabrese; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Meeting abstract

Medical understanding systemic lupus erythematosus (SLE) has evolved dramatically since its first reference during the 1100s, through the neoclassic period of the 1800s when researchers began to refine the definition, and into the modern era with transformative laboratory investigations and discoveries altering the diagnosis and treatment. Weaved into this historic overview are descriptions of the most important contributions of the leading practitioners and researchers.

Additional file 1 contains an edited transcript of the full presentation.

Additional file 1.

Format: PDF Size: 160KB Download file

This file can be viewed with: Adobe Acrobat Reader

Competing interests

LHC has received consulting fees from Amgen, BMS, Centecor, Genentech/Roche, Pfizer, Sanofi Aventis and Savient.